Metastat Inc (MTST) 0.3350 $MTST SeeThruEquity Initiates

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Metastat Inc (MTST) 0.3350 $MTST

SeeThruEquity Initiates Coverage on MetaStat, Inc. with a Price Target of $1.23
ACCESSWIRE - Thu Jun 25, 7:31AM CDT
NEW YORK, NY / ACCESSWIRE / June 25, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of MetaStat, Inc. (OTCQB: MTST) with a price target of $1.23.

MetaStat reports change in executive positions
M2 - Fri Jun 19, 3:44AM CDT
Molecular diagnostic company MetaStat (OtherOTC:MTST) revealed on Wednesday the addition of Douglas A. Hamilton as its president and chief executive officer.

New chief at MetaStat
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 8:42AM CDT


MetaStat, Inc. Announces Douglas A. Hamilton Named President, Chief Executive Officer
Business Wire - Thu Jun 18, 7:00AM CDT
MetaStat, Inc. (OTCQB:MTST), announced that Douglas A. Hamilton has been elected as President and Chief Executive Officer of the company. Mr. Hamilton has consulted for the company as acting Chief Financial Officer since August 2014.
HSP: 89.15 (+0.02)

MetaStat To Present at SeeThruEquity Conference in New York City on May 28
ACCESSWIRE - Wed May 20, 10:00AM CDT
Presentation to Be Webcast

MetaStat Demonstrates MenaCalc Lung(TM) Is Prognostic for Outcome in Non-Small Cell Lung Cancer
Business Wire - Tue Apr 21, 12:00PM CDT
--Support Usefulness of MenaCalc(TM) as Prognostic Test for Predicting Outcome Beyond Early-Stage Breast Cancer to Include Squamous Cell Carcinoma of Lung

MetaStat CEO Oscar L. Bronsther, M.D. to Participate in Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa on April 17
Business Wire - Tue Apr 14, 6:30AM CDT
Oscar L. Bronsther, M.D., CEO of MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will participate in a panel discussion at the Moffitt Cancer Center's 9th Annual Business of Biotech Conference in Tampa, FL on Friday, April 17.

MetaStat Discussed in Medscape and Other News Outlets
Business Wire - Thu Apr 09, 6:30AM CDT
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, was featured in Medscape.com, WNYM-AM, WHCR-FM and the Boston Business Journal.

MetaStat Appoints Martin J. Driscoll to Board of Directors
Business Wire - Tue Apr 07, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has appointed Martin J. Driscoll to its Board of Directors, effective immediately.

MetaStat Announces Closing of Series B Private Placement
Business Wire - Tue Mar 31, 4:43PM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, announced today the final closing of its Series B Preferred Stock private placement (the "Offering" resulting in total gross proceeds of $3.4 million. Institutional and accredited investors including certain members of the company's board of directors and management participated in the transaction. H.C. Wainwright & Co., LLC acted as lead placement agent. Alere Financial Partners, LLC, a division of Clancy Financial Services Inc. acted as co-placement agent.

MetaStat Enters into Agreement to Access Tumor Samples and Clinical Data from Kaiser Foundation Hospitals
Business Wire - Tue Jan 27, 7:56AM CST
MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has executed a material/data transfer agreement with Kaiser Foundation Hospitals. Under the terms of the agreement, MetaStat will receive de-identified tissue samples, clinical data and medical histories for up to 500 patients with or without metastatic breast cancer for testing using the Company's MetaSite Breast(TM) and MenaCalc Breast(TM) diagnostic assays for the early and reliable prediction of systemic metastasis.

MetaStat Closes First Round of a $3.5 Million Private Placement
Business Wire - Tue Jan 06, 10:23AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has consummated an initial closing of $1.3 million in a private placement of up to $3.5 million of shares of its Series B Preferred Stock to institutional and accredited investors including certain members of the Company's Board of Directors.

MetaStat to Present at Biotech Showcase 2015 in San Francisco
Business Wire - Tue Jan 06, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, will be a presenting company at the Biotech Showcase(TM) 2015 Conference to be held at the Parc 55 Wyndham San Francisco-Union Square Hotel in San Francisco, CA.

ATS Labs Announces New Name and Introduces New CEO
PR Newswire - Mon Dec 08, 7:30AM CST
ATS Labs is happy to announce that it is changing its company name to Accuratus Lab Services. ATS Labs recently completed a large acquisition of the assets of Microtest Laboratories of Agawam, Massachusetts, enabling it to expand its service offering into the growing medical device and pharmaceutical market segments. Company Executive Chairman Tom Burnell said, "The new identity and logo had to satisfy all of the existing expectations and strengths associated with the historical ATS Labs and Microtest Laboratories businesses while simultaneously personifying the scientific experience, quality solutions and accurate test results the combined companies provide to the growing medical device, biopharmaceutical and antimicrobial industries." Accuratus is derived from the Latin word accurate.

MetaStat Completes Divestiture of Its Therapeutic Assets
Business Wire - Tue Dec 02, 6:30AM CST
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has completed the divestiture of its therapeutic assets. As a result of this divestiture, MetaStat's sole focus is developing its MetaSite Breast(TM) and MenaCalc(TM) near-term product opportunities.

MetaStat Spotlighted in Three Publications
Business Wire - Mon Oct 27, 6:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, was the subject of recent articles in Boston Magazine, Medical Device Daily and MedCity News.

MetaStat Appoints Richard J. Berman and H. Philip Goodeve to Board of Directors
Business Wire - Tue Oct 21, 7:55AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, appointed Richard J. Berman and H. Philip Goodeve to its Board of Directors, effective October 15. Mr. Berman and Mr. Goodeve replace Warren Lau and Dr. Patrick Mooney, both of whom have resigned from the Board. In addition, Johan M. (Thijs) Spoor has resigned as Chairman of the Board while remaining a Board member.

MetaStat's Diagnostic Technology Spotlighted in WABC-TV News Special on October 4
Business Wire - Wed Oct 08, 7:30AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, has its licensed technology spotlighted in a WABC-TV news special that aired on Saturday, October 4.

MetaStat to Present at 13th Annual BIO Investor Forum on October 8 in San Francisco
Business Wire - Mon Oct 06, 7:01AM CDT
MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on understanding and treating systemic metastasis, announced that Oscar L. Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the 13th Annual BIO Investor Forum on October 8, 2014 at 2:00 pm PDT in San Francisco. Dr. Bronsther will provide an update on the Company's business activities.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 170

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 88

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 10

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 122

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 17

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 160

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading